Covidien, a global provider of healthcare products, has launched its "1 in 1,000" campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.
"1 in 1,000" refers to the number of women who are likely to experience a potentially life-threatening blood clot during pregnancy, delivery or postpartum, and includes both deep vein thrombosis and pulmonary embolism.
"The increased incidence of VTE during pregnancy and the peripartum period warrants special consideration and preventive intervention," said Randall Kuhlmann, MD, PhD, director of the Maternal Fetal Medicine Section and Maternal Fetal Care Center at Children's Hospital of Wisconsin and Froedtert Hospital. "As an obstetrician, it is my job to protect my patients from this preventable disease by facilitating education and following the recommended guidelines for prophylaxis."
Developed in consultation with leading women's health experts, the "1 in 1,000" education and prevention program focuses on empowering healthcare professionals to take action against VTE.
The program includes guidelines and materials on how to educate pregnant patients on the risks of VTE and highlights the importance of appropriate VTE risk assessment - as well as prevention protocols at hospitals and health systems.
The Association of periOperative Registered Nurses (AORN) awarded its Seal of Recognition for components of the "1 in 1,000" campaign, which was announced earlier this year at the 2012 annual meeting of the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN)..
More information and materials can be accessed at www.covidien.com/1in1000.